Erschienen in:
06.08.2016 | Original Article
Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer
verfasst von:
Nasim Kheshtchin, Samaneh Arab, Maryam Ajami, Reza Mirzaei, Mahboubeh Ashourpour, Neda Mousavi, Najmeh Khosravianfar, Farhad Jadidi-Niaragh, Afshin Namdar, Farshid Noorbakhsh, Jamshid Hadjati
Erschienen in:
Cancer Immunology, Immunotherapy
|
Ausgabe 10/2016
Einloggen, um Zugang zu erhalten
Abstract
Considerable evidence shows that the tumor microenvironment is an active participant in preventing immunosurveillance and limiting the efficacy of anticancer therapies. Hypoxia is a prominent characteristic of the solid tumor microenvironment. The transcription factor hypoxia-inducible factor-1α (HIF-1α) is an important mediator of hypoxic response of tumor cells that modulates the expression of specific genes involved in tumor immunosuppression. Using a 4T1 breast cancer model, we show that in vivo administration of PX-478, an inhibitor of oxygen-sensitive HIF-1α, led to reduced expression of Foxp3 and VEGF transcript and/or protein, molecules that are directly controlled by HIF-1. When combined with dendritic cell (DC)-based vaccination, HIF-1α inhibition resulted in an augmented cytotoxic T lymphocyte effector function, improved proliferation status of T cells, increased production of inflammatory cytokine IFN-γ, as well as reduced regulatory function of T cells in association with slower tumor growth. Taken together, our findings indicate that the use of HIF-1α inhibition provides an immune adjuvant activity, thereby improves the efficacy of tumor antigen-based DC vaccine.